X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with Prime Securities - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs PRIME SECURITIES - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

PRIME SECURITIES 
   Change

Prime Securities is promoted by the Sheths which is also the controlling family of Great Eastern Shippng Company. The company offers financial services in the field of corporate finance, capital markets advisory, and broking. The company also establi... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES PRIME SECURITIES INDOCO REMEDIES/
PRIME SECURITIES
 
P/E (TTM) x 90.2 8.8 1,025.1% View Chart
P/BV x 3.2 186.6 1.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 INDOCO REMEDIES   PRIME SECURITIES
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
PRIME SECURITIES
Sep-13
INDOCO REMEDIES/
PRIME SECURITIES
5-Yr Chart
Click to enlarge
High Rs36015 2,371.1%   
Low Rs2492 12,455.0%   
Sales per share (Unadj.) Rs119.0-12.1 -979.9%  
Earnings per share (Unadj.) Rs8.4-32.8 -25.5%  
Cash flow per share (Unadj.) Rs15.2-32.5 -46.9%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.70.2 30,681.5%  
Shares outstanding (eoy) m92.1526.47 348.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.6-0.7 -361.6%   
Avg P/E ratio x36.4-0.3 -13,879.4%  
P/CF ratio (eoy) x20.0-0.3 -7,560.9%  
Price / Book Value ratio x4.337.3 11.5%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,083228 12,336.3%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,16769 3,126.6%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,968-322 -3,411.4%  
Other income Rs m40-35 -114.1%   
Total revenues Rs m11,007-356 -3,089.4%   
Gross profit Rs m1,565-694 -225.4%  
Depreciation Rs m6337 9,171.0%   
Interest Rs m62128 48.4%   
Profit before tax Rs m909-864 -105.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1393 4,623.3%   
Profit after tax Rs m771-867 -88.9%  
Gross profit margin %14.3215.9 6.6%  
Effective tax rate %15.3-0.3 -4,393.0%   
Net profit margin %7.0269.7 2.6%  
BALANCE SHEET DATA
Current assets Rs m5,7251,914 299.1%   
Current liabilities Rs m5,4542,795 195.1%   
Net working cap to sales %2.5274.2 0.9%  
Current ratio x1.00.7 153.3%  
Inventory Days Days620-  
Debtors Days Days72-1,467 -4.9%  
Net fixed assets Rs m5,30754 9,865.0%   
Share capital Rs m184133 138.8%   
"Free" reserves Rs m6,331-143 -4,424.3%   
Net worth Rs m6,5166 106,811.5%   
Long term debt Rs m1,3231 94,507.1%   
Total assets Rs m11,9702,817 424.9%  
Interest coverage x15.6-5.7 -272.8%   
Debt to equity ratio x0.20.2 88.5%  
Sales to assets ratio x0.9-0.1 -802.9%   
Return on assets %7.0-26.2 -26.5%  
Return on equity %11.8-14,214.8 -0.1%  
Return on capital %12.4-9,810.7 -0.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,5070-   
Fx outflow Rs m1,1410-   
Net fx Rs m3,3660-   
CASH FLOW
From Operations Rs m886-404 -219.3%  
From Investments Rs m-1,706393 -434.0%  
From Financial Activity Rs m1,316-196 -670.2%  
Net Cashflow Rs m497-207 -239.4%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.2 6,250.0%  
FIIs % 6.0 1.9 315.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 98.0 22.9%  
Shareholders   12,805 25,229 50.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   FINOLEX IND.  EDELWEISS FINANCIAL  TALWALKARS BETTER VAL.  TVS SRICHAKRA  CCL INTERNATIONAL  



Today's Market

Sensex Trades Lower; Infosys & Yes Bank Top Losers(12:30 pm)

Share markets in India are presently trading on a negative note. Sectoral indices are trading mixed with stocks in the capital goods sector and metal sector.

Related Views on News

PRIME SECURITIES Announces Quarterly Results (2QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, PRIME SECURITIES has posted a net profit of Rs 37 m (up 6.6% YoY). Sales on the other hand came in at Rs 94 m (up 53.7% YoY). Read on for a complete analysis of PRIME SECURITIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 139.4% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, INDOCO REMEDIES has posted a net profit of Rs 78 m (down 139.4% YoY). Sales on the other hand came in at Rs 2 bn (down 17.3% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Dec 18, 2018 03:35 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS